Genenta Science shares surge 21.54% after-hours after strategic pivot to defense, ATC acquisition, and rebrand to Saentra Forge.

Genenta Science (NASDAQ: GNTA) surged 21.54% in after-hours trading following its announcement of a strategic pivot from biotech to defense and national security sectors. The company revealed plans to rebrand as Saentra Forge S.p.A., targeting acquisitions of Italian defense firms under Golden Power regulations, including a binding agreement to invest in ATC, a high-precision defense manufacturer. The move, supported by Praexidia Foundation—a shareholder linked to Italian defense institutions—positions the company to consolidate profitable, national-security-focused businesses. ATC’s strong 2026-2027 revenue and EBITDA projections, along with Genenta’s projected $33 million in cash reserves, underscored investor optimism. The pivot marks a departure from gene therapy development, emphasizing industrial consolidation and institutional alignment, aligning with the stock’s sharp post-announcement rally.